cladribine 治疗期间 COVID-19 后正常的抗体反应。
Normal antibody response after COVID-19 during treatment with cladribine.
机构信息
Department of Neurology, Oslo University Hospital and Faculty of Medicine, University of Oslo, Oslo, Norway.
出版信息
Mult Scler Relat Disord. 2020 Nov;46:102476. doi: 10.1016/j.msard.2020.102476. Epub 2020 Aug 29.
Abstract
Cladribine is a highly effective, recently available treatment in multiple sclerosis. This case report describes a patient with COVID-19 infection during second year treatment with cladribine. The infection was mild and she was able to mount an adequate immune response with detectable antibodies three months later.
摘要
克拉屈滨是一种高效的、最近可用的多发性硬化症治疗药物。本病例报告描述了一名患者在接受克拉屈滨治疗的第二年感染了 COVID-19。该感染为轻症，她在 3 个月后产生了可检测到的抗体，从而能够产生充分的免疫应答。
相似文献
1
Normal antibody response after COVID-19 during treatment with cladribine. cladribine 治疗期间 COVID-19 后正常的抗体反应。
Mult Scler Relat Disord. 2020 Nov;46:102476. doi: 10.1016/j.msard.2020.102476. Epub 2020 Aug 29.
2
Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tablets.接受克拉屈滨片治疗的多发性硬化症患者感染新冠病毒后的良好预后。
Mult Scler Relat Disord. 2020 Nov;46:102469. doi: 10.1016/j.msard.2020.102469. Epub 2020 Aug 27.
3
Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies?超越 COVID-19：接受抗 CD20 治疗的多发性硬化症/视神经脊髓炎谱系疾病患者是否会产生 SARS-CoV2 抗体？
Mult Scler Relat Disord. 2020 Nov;46:102482. doi: 10.1016/j.msard.2020.102482. Epub 2020 Sep 3.
4
Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia.一名使用奥瑞珠单抗且患有低丙种球蛋白血症的患者对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的抗体反应减弱。
Mult Scler Relat Disord. 2020 Sep;44:102315. doi: 10.1016/j.msard.2020.102315. Epub 2020 Jun 20.
5
Longitudinal humoral response in MS patients treated with cladribine tablets after receiving the second and third doses of SARS-CoV-2 mRNA vaccine.多发性硬化症患者在接受第二和第三剂 SARS-CoV-2 mRNA 疫苗后用克拉屈滨片治疗的纵向体液反应。
Mult Scler Relat Disord. 2022 Jul;63:103863. doi: 10.1016/j.msard.2022.103863. Epub 2022 May 10.
6
COVID-19 in Cladribine-treated patient with multiple sclerosis.COVID-19 于接受克拉屈滨治疗的多发性硬化症患者中。
J Neuroimmunol. 2021 Oct 15;359:577690. doi: 10.1016/j.jneuroim.2021.577690. Epub 2021 Aug 8.
7
Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice. cladribine 治疗多发性硬化症的轻度或无 COVID-19 症状：两例病例及对临床实践的影响。
Mult Scler Relat Disord. 2020 Oct;45:102452. doi: 10.1016/j.msard.2020.102452. Epub 2020 Aug 16.
8
[Vaccination against SARS-CoV-2 in patients with multiple sclerosis].[多发性硬化症患者的新型冠状病毒2型疫苗接种]
Rev Neurol. 2021 Apr 1;72(7):250-260. doi: 10.33588/rn.7207.2021097.
9
Effect of cladribine on COVID-19 serology responses following two doses of the BNT162b2 mRNA vaccine in patients with multiple sclerosis.氯法拉滨对多发性硬化症患者接种两剂 BNT162b2 mRNA 疫苗后 COVID-19 血清学反应的影响。
Mult Scler Relat Disord. 2022 Jan;57:103343. doi: 10.1016/j.msard.2021.103343. Epub 2021 Oct 23.
10
Development of SARS-CoV-2 IgM and IgG antibodies in a relapsing multiple sclerosis patient on ofatumumab.奥法妥木单抗治疗复发性多发性硬化症患者中 SARS-CoV-2 免疫球蛋白 M 和 G 抗体的产生。
Mult Scler Relat Disord. 2021 Apr;49:102777. doi: 10.1016/j.msard.2021.102777. Epub 2021 Jan 19.
引用本文的文献
1
Cladribine Tablets Mode of Action, Learning from the Pandemic: A Narrative Review.克拉屈滨片的作用机制：从大流行中汲取经验的叙述性综述
Neurol Ther. 2023 Oct;12(5):1477-1490. doi: 10.1007/s40120-023-00520-6. Epub 2023 Jul 8.
2
Cladribine Tablets for Relapsing-Remitting Multiple Sclerosis: A Clinician's Review.用于复发缓解型多发性硬化症的克拉屈滨片：临床医生综述
Neurol Ther. 2022 Jun;11(2):571-595. doi: 10.1007/s40120-022-00339-7. Epub 2022 Mar 23.
3
Multiple Sclerosis Patients and Disease Modifying Therapies: Impact on Immune Responses against COVID-19 and SARS-CoV-2 Vaccination.多发性硬化症患者与疾病修正疗法：对针对2019冠状病毒病和严重急性呼吸综合征冠状病毒2疫苗接种的免疫反应的影响
Vaccines (Basel). 2022 Feb 11;10(2):279. doi: 10.3390/vaccines10020279.
4
Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets. cladribine 片剂治疗多发性硬化症患者的接种机会。
Curr Neuropharmacol. 2022;20(10):1811-1815. doi: 10.2174/1570159X20666211217160451.
5
Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice.关于2019冠状病毒病疫苗接种及克拉屈滨片在临床实践中的应用的专家意见。
Ther Adv Neurol Disord. 2021 Dec 7;14:17562864211058298. doi: 10.1177/17562864211058298. eCollection 2021.
6
Vaccination in multiple sclerosis patients treated with highly effective disease-modifying drugs: an overview with consideration of cladribine tablets.接受高效疾病修正药物治疗的多发性硬化症患者的疫苗接种：对克拉屈滨片的概述及考量
Ther Adv Neurol Disord. 2021 Jul 22;14:17562864211019598. doi: 10.1177/17562864211019598. eCollection 2021.
7
COVID-19 in Cladribine-treated patient with multiple sclerosis.COVID-19 于接受克拉屈滨治疗的多发性硬化症患者中。
J Neuroimmunol. 2021 Oct 15;359:577690. doi: 10.1016/j.jneuroim.2021.577690. Epub 2021 Aug 8.
8
Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations.多发性硬化症、疾病修正疗法与2019冠状病毒病：关于免疫反应和疫苗接种建议的系统综述
Vaccines (Basel). 2021 Jul 11;9(7):773. doi: 10.3390/vaccines9070773.
9
Humoral response to SARS-CoV-2 COVID-19 vaccines in patients with multiple sclerosis treated with immune reconstitution therapies.体液对免疫重建治疗的多发性硬化症患者 SARS-CoV-2 COVID-19 疫苗的反应。
Mult Scler Relat Disord. 2021 Sep;54:103150. doi: 10.1016/j.msard.2021.103150. Epub 2021 Jul 15.
10
The Significance of COVID-19 Immunological Status in Severe Neurological Complications and Multiple Sclerosis-A Literature Review.新型冠状病毒肺炎免疫状态在严重神经系统并发症和多发性硬化症中的意义——文献综述。
Int J Mol Sci. 2021 May 31;22(11):5894. doi: 10.3390/ijms22115894.
本文引用的文献
1
Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia.一名使用奥瑞珠单抗且患有低丙种球蛋白血症的患者对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的抗体反应减弱。
Mult Scler Relat Disord. 2020 Sep;44:102315. doi: 10.1016/j.msard.2020.102315. Epub 2020 Jun 20.
2
Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis.新型冠状病毒肺炎合并多发性硬化患者的临床特征和结局。
JAMA Neurol. 2020 Sep 1;77(9):1079-1088. doi: 10.1001/jamaneurol.2020.2581.
3
Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS).接受过克拉屈滨片治疗患者的长期疗效：意大利多发性硬化症登记处（CLARINET-MS）的真实世界分析
Ther Adv Neurol Disord. 2020 Jun 10;13:1756286420922685. doi: 10.1177/1756286420922685. eCollection 2020.
4
The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.与 COVID-19 大流行期间多发性硬化症疾病修正治疗相关的基础生物学。
Mult Scler Relat Disord. 2020 Aug;43:102174. doi: 10.1016/j.msard.2020.102174. Epub 2020 May 12.
5
An Italian programme for COVID-19 infection in multiple sclerosis.一项针对多发性硬化症患者新冠病毒感染情况的意大利项目。
Lancet Neurol. 2020 Jun;19(6):481-482. doi: 10.1016/S1474-4422(20)30147-2. Epub 2020 Apr 30.
6
Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic.在2019冠状病毒病大流行期间治疗多发性硬化症和视神经脊髓炎谱系障碍。
Neurology. 2020 Jun 2;94(22):949-952. doi: 10.1212/WNL.0000000000009507. Epub 2020 Apr 2.
7
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.多发性硬化症患者接受芬戈莫德、那他珠单抗、利妥昔单抗和注射治疗的感染风险。
JAMA Neurol. 2020 Feb 1;77(2):184-191. doi: 10.1001/jamaneurol.2019.3365.
8
Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.克拉屈滨片对复发型多发性硬化患者淋巴细胞减少和重建动力学的影响。
Mult Scler Relat Disord. 2019 Apr;29:168-174. doi: 10.1016/j.msard.2019.01.038. Epub 2019 Jan 24.
9
Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.克拉屈滨片治疗多发性硬化症患者的安全性：综合分析。
Mult Scler Relat Disord. 2019 Apr;29:157-167. doi: 10.1016/j.msard.2018.11.021. Epub 2018 Nov 20.
Zotero 插件